Ryan Shawcross is handing over a rejuvenated Stoke City to Mark Robins after a fiercely hard-working draw at promotion-chasing Burnley. Stoke might have found a moment to win this match of few ...

Zilurgisertib fumarate (INCB-00928) is under development for the treatment of fibrodysplasia ossificans progressiva, anemia associated with myelofibrosis, primary myelofibrosis, post essential ...

Venetoclax is under clinical development by AbbVie and currently in Phase II for Aplastic Anemia. According to GlobalData, Phase II drugs for Aplastic Anemia have a 67% phase transition success rate ...

At just eight years old, Elam has seen his childhood stripped away, battling severe aplastic anaemia, a rare and life-threatening blood disorder. Elam, whose surname has been withheld, no longer ...

During a Case-Based Roundtable® event, Andrew Kuykendall, MD, discussed treatment for a 68-year-old patient with intermediate-1 risk myelofibrosis and mild anemia. KUYKENDALL: This patient has good ...

You can also be susceptible to getting infections or anemia (low red blood cells), as well as other symptoms with myeloproliferative ... With essential thrombocythemia, a CBC would show a high ...

Anaemia in myelofibrosis is a multifaceted challenge with a significant impact on patient outcomes, writes Theresa Lowry Lehnen Myelofibrosis is a rare, chronic myeloproliferative neoplasm ...

which was approved for patients with myelofibrosis with anemia.3 Ultimately, the important thing is to make sure patients are living longer but also living better, Jain said, referencing a ...

The company's lead product, bitopertin, is being developed for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). DISC-0974, another key asset, is aimed at treating anemia in ...

In addition to CK0804, Cellenkos' CK0801 candidate for aplastic anemia has shown promising efficacy, including transfusion independence in treated patients. Myelofibrosis is a rare, chronic, and ...

The early treatment of anemia in eligible patients with MF should be a primary consideration according to the review. Patients with different types of myelofibrosis (MF) and anemia, their traditional ...